Multicentre, randomised, controlled trial of the EU-Japan Joint Virtual Coaching System (e-VITA) to improve the quality of life of older people - a proof-of-concept study.

Multicentre, randomised, controlled trial of the EU-Japan Joint Virtual Coaching System (e-VITA) to improve the quality of life of older people - a proof-of-concept study. - Multicentre, randomised, controlled trial of the EU-Japan Joint Virtual Coaching System (e-VITA) to improve the quality of life of older people - a proof-of-concept study.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000050378

Enrollment

240

Registered

2023-02-18

Start date

2023-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy women and men

Interventions

A virtual coach is set up in their home and used for a period of six months. They also receive digital support from a human coach and fortnightly advice on behaviour change by phone. The control group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -who are willing to participate in the study and meet the eligibility criteria -Be 65 years of age or older and retired. -Able to understand and consent to an explanation. -Able to walk independently. -MoCA>22 (no significant cognitive impairment). -GDS <9 (not depressed). -SPPB > 7 (including 7 and no motor impairment). -Clinical Frailty Scale score between 2 and 4. -Has a good understanding of the Japanese language. -Consent to participate in the study.

Exclusion criteria

Exclusion criteria: Exclusion criteria. Failure to meet the inclusion criteria. Use of active implants or non-implant medical devices. Allergy to nickel. Concurrent participation in other trials. Lack of written informed consent. Myocardial infarction or stroke within 6 months. Painful arthritis, scoliosis, amputation of any limb, painful foot lesions or neuropathy limiting balance and mobility. Uncontrolled hypertension. Patients with a pacemaker or implantable cardioverter-defibrillator. Advanced Parkinson's disease or other neuromuscular disorders. Metastatic cancer or immunosuppressive therapy. Significant visual or hearing impairment.

Design outcomes

Primary

Measure	Time frame
QOL measured by EQ-5D-5L	—

Countries

Japan,Europe

Contacts

Public ContactToshimi Ogawa

Tohoku University Smart Aging Research Center

toshimi.ogawa.e6@tohoku.ac.jp0227178561

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026